The University of Dublin | Trinity College -- Ollscoil Átha Cliath | Coláiste na Tríonóide
Trinity's Access to Research Archive
Home :: Log In :: Submit :: Alerts ::

School of Medicine >
Histopathology & Morbid Anatomy >
Histopathology & Morbid Anatomy (Scholarly Publications) >

Please use this identifier to cite or link to this item:

Title: Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review.
Other Titles: Oxaliplatin in Cisplatin-Resistant Cancer
Author's Homepage:
Keywords: Cisplatin
Issue Date: 2007
Publisher: WB Saunders
Citation: Stordal, B., Pavlakis, N. and Davey, R., Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review., Cancer Treatment Reviews, 33, 4, 2007, 347 - 357
Series/Report no.: Cancer Treatment Reviews;33, 4
Abstract: Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with “cisplatinresistant” cancer. We identified 25 pre-clinical cell models of platinum resistance and 24 clinical trials reporting oxaliplatin based salvage therapy for cisplatin-resistant cancer. The pre-clinical data suggests that there is cross-resistance between cisplatin and oxaliplatin in low-level resistance models. In models with high level resistance (>10 fold) there is less cross resistance between cisplatin and oxaliplatin, which may be a reason why oxaliplatin is thought to be active in cisplatin-resistant cancer. In clinical trials where oxaliplatin has been used as part of salvage therapy for patients who have failed cisplatin or carboplatin combination chemotherapy, there was a much lower response rate in patients with platinum-refractory or resistant cancers compared to platinum-sensitive cancers. This suggests that there may be cross-resistance between cisplatin and oxaliplatin in the clinic. Oxaliplatin as a single agent had a poor response rate in cisplatin refractory and resistant cancer. Oxaliplatin performed better in combination with other agents for the treatment of platinum resistant/refractory cancer suggesting that the benefit of oxaliplatin may lie in its more favourable toxicity and ability to be combined with other drugs rather than an underlying activity in cisplatin resistance. Oxaliplatin therefore should not be considered broadly active in cisplatin-resistant cancer.
Description: PUBLISHED
Appears in Collections:Histopathology & Morbid Anatomy (Scholarly Publications)

Files in This Item:

File Description SizeFormat
2007-Stordal-CTR-Oxaliplatin.pdfPublished (author's copy) - Peer Reviewed262.51 kBAdobe PDFView/Open

This item is protected by original copyright

Please note: There is a known bug in some browsers that causes an error when a user tries to view large pdf file within the browser window. If you receive the message "The file is damaged and could not be repaired", please try one of the solutions linked below based on the browser you are using.

Items in TARA are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback